



Transitioning Treatment

Through New Immunological Pathways in

Inflammatory Bowel Disease

Sunday, October 25 · 6:15 PM – 7:45 PM EDT

Agenda

Introduction

William J. Sandborn, MD

Targeting Immunological Pathways in IBD

Bruce E. Sands MD, MS

How Emerging Agents are Performing in Safety and Efficacy in Moderate to Severe UC

Kim L. Isaacs, MD, PhD

How Emerging Agents are Performing in Safety and Efficacy in Moderate to Severe Crohn's Disease

William J. Sandborn, MD

LIVE Question & Answer

Activity Chair



William J. Sandborn, MD

Distinguished Professor of Medicine
Chief, Division of Gastroenterology
Director, UCSD IBD Center
UC San Diego Health System
La Jolla, CA

Faculty



Kim L. Isaacs, MD, PhD

Professor of Medicine
University of North Carolina
Chapel Hill, NC



Bruce E. Sands, MD, MS

Chief, Dr. Henry D. Janowitz
Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine
at Mount Sinai Hospital and
Mount Sinai Health System
New York, NY

Overview

Drs. Sandborn, Isaacs, and Sands will summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for the treatment of moderate-to-severe inflammatory bowel disease (IBD). They will evaluate the most recent clinical findings on the safety and efficacy of therapies that target immunological pathways. They will also assess therapeutic regimens for moderate-to-severe IBD for their ability to improve outcomes in patients who are tumor necrosis factor (TNF) inhibitor-naïve or have previously received TNF inhibitors. Add this CME Virtual Satellite Symposium to your Virtual ACG 2020 schedule today!



Learning Objectives

Upon successful completion of this activity, participants should be better able to:

- Summarize new evidence about investigational agents with unique mechanisms of action in late stage development for the treatment of moderate to severe IBD.
- Assess new clinical findings on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe inflammatory bowel disease.
- Compare therapeutic regimens for moderate to severe inflammatory bowel disease for their ability to improve outcomes in patients who are tumor necrosis factor (TNF) inhibitor-naïve, as well as those who have received TNF inhibitors.

Target Audience

The intended audience for this activity is gastroenterologists, advanced practice providers, and other health care professionals involved in the management of patients with IBD.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical

Education's Standards for Commercial Support, all planners, teachers, and authors involved in the development of accredited content are required to disclose to the accredited provider their **relevant financial relationships**. Relevant financial relationships will be mitigated and disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

Questions? Contact us at Questions@VindicoCME.com